Skip to main content
Premium Trial:

Request an Annual Quote

Quanterix, BioMérieux Ink Licensing Deal

NEW YORK (360Dx) – Quanterix announced on Monday it and BioMérieux have signed a new licensing deal giving both firms greater flexibility to commercialize products within their respective fields.

As part of the new agreement, Quanterix will have broader licensing rights within the in vitro diagnostic field, and it and BioMérieux will have the ability to develop instruments for commercialization within the IVD space, Quanterix said.

BioMérieux gained access to Quanterix's Simoa technology in late 2012.

Lexington, Massachusetts-based Quanterix said that under the new agreement, it can further license its Simoa technology, as well as go directly to market with a new point-of-care device or laboratory-developed test. Within the time frame of the agreement, which was not disclosed, BioMérieux retains the rights to develop the technology focusing on its strategic priorities.

Quanterix is entitled to a one-time milestone payment and to royalties based on commercial sales from BioMérieux. Further terms of the deal were not disclosed.